Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Non-small cell lung cancer (NSCLC) treatment often involves Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like Erlotinib.
• Acquired resistance to EGFR-TKIs is a significant clinical challenge, frequently mediated by EGFR T790M mutations or increased Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) expression.

Purpose of the Study:

• To investigate the mechanisms underlying EGFR-TKI resistance in NSCLC.
• To evaluate the role of VEGFR-2 and its co-receptor Neuropilin-1 (NP-1) in acquired resistance to Erlotinib.
• To assess the efficacy of combining Erlotinib with a VEGFR-2 inhibitor in EGFR-mutated NSCLC.

Main Methods:

• Utilized NSCLC cell lines with EGFR mutations and acquired Erlotinib resistance.
• Analyzed gene and protein expression of VEGF, VEGFR-2, and NP-1 using quantitative methods.
• Performed immunofluorescence, Fluorescence-Activated Cell Sorting (FACS), cell proliferation assays, and Kaplan-Meier survival analysis.

Main Results:

• Upregulated expression of VEGF, VEGFR-2, and NP-1 was observed in Erlotinib-resistant and EGFR double-mutant (L858R/T790M) NSCLC cells.
• Increased VEGFR-2 and NP-1 expression was confirmed in resistant cell lines via immunofluorescence and FACS.
• Combined Erlotinib and VEGFR-2 inhibitor treatment significantly reduced cell survival in double-mutant NSCLC cells (9% vs. 72% with Erlotinib alone).
• High VEGFR-2 expression correlated with shorter median survival in late-stage NSCLC patients.

Conclusions:

• VEGFR-2 is implicated as a key mediator of EGFR-TKI resistance in NSCLC.
• Combined therapy with Erlotinib and a VEGFR-2 inhibitor shows promise for treating EGFR-mutated NSCLC.
• Targeting VEGFR-2 may overcome or prevent resistance to EGFR-TKIs in NSCLC patients.